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Abstract
Alternative splicing of caspase-3 produces a short isoform caspase-3s that antagonizes caspase-3 apoptotic activity.
However, the mechanism of apoptosis inhibition by caspase-3s remains unknown. Here we show that exogenous caspase-3
sensitizes MCF-7 and HBL100 breast cancers cells to chemotherapeutic treatments such as etoposide and methotrexate
whereas co-transfection with caspase-3s strongly inhibits etoposide and methotrexate-induced apoptosis underlying thus
the anti-apoptotic role of caspase-3s. In caspase-3 transfected cells, lamin-A and a-fodrin were cleaved when caspase-3 was
activated by etoposide or methotrexate. When caspase-3s was co-transfected, this cleavage was strongly reduced.
Depletion of caspase-3 by RNA interference in HBL100 containing endogenous caspase-3s caused reduction in etoposide
and methotrexate-induced apoptosis, whereas the depletion of caspase-3s sensitized cells to chemotherapy. In the
presence of caspase-3s, a lack of interaction between caspase-3 and caspase-9 was observed. Immunoprecipitation assays
showed that caspase-3s binds the pro-forms of caspase-3. This result suggested that the absence of interaction with
caspase-9 when both variants of caspase-3 are present contribute to block the apoptosome assembly and inhibit apoptosis.
These data support that caspases-3s negatively interferes with caspase-3 activation and apoptosis in breast cancer, and that
it can play key roles in the modulation of response to chemotherapeutic treatments.
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Introduction
Caspases are a family of evolutionary conserved cysteine
proteases that play a central role in a majority of apoptotic cell
death pathways. Death signals activate the proteolytic cascade of
caspases through two main pathways, i.e. an extrinsic pathway
that starts at the level of plasma membrane death receptors and an
intrinsic pathway that activation is a response to irreversible
cellular damage [1]. Both pathways converge to the activation of
caspase-3, the closer homolog of the in Caenorhabditis elegans CED-3
[2]. Procaspase-3 is a 32 kDa caspase-3 zymogen (also known as
CPP32). CPP32 exists in the cells as inactive dimmers. Its
proteolytic cleavage on C-terminal side of aspartate residues
eliminates the pro-domain, separates the remaining protein into a
large and a small subunit and generates an active tetramer
constituted by two large and two small subunits. In turn, caspase-3
activates downstream enzymes of the caspase family and
contributes with them to generate the characteristic apoptotic cell
death phenotype.
Activation of caspase-3 is required for membrane bleeding and
internucleosomal DNA fragmentation that occur during apoptosis.
Caspase activity is regulated at several levels, including gene
transcription and post-translational modifications. The alternative
splicing of caspase genes generates full-length and truncated
proteins whose functions can be antagonistic [3]. This character-
istic maintains the threshold of response to certain levels of stimuli
[4].
The human Caspase-3 gene is located on 4q33-q35.1 and
possesses 2635 base pairs leading to 7 exons. Its alternative splicing
generates two transcripts, caspase-3 and caspase-3s that were
detected in all the studied tissues [5] and may have different
apoptotic activities [5,6]. The principal mRNA variant, caspase-3,
is 834 base-long and the short transcript, caspase-3s, has lost the
sixth exon leading to a loss of 122 bases (representing 95 amino-
acids initially present in the procaspase-3 protein). The lost
sequence includes the short subunit and the C-terminal part of the
long subunit in which is located the QACRG motif that
participates in the formation of the catalytic site. The caspase-3s
protein has around a 20 KDa molecular weight and expression of
the short isoform of caspase-3 in 293T cells prevents DNA
fragmentation and poly(ADP-ribose) polymerase 1 (PARP1)
cleavage in response to an apoptotic stimulus [5].
The role of caspase-3 in the response of breast cancer cells to
chemotherapeutic drugs remains a controversial issue. The lost of
caspase-3 expression as well as defaults in cytochrome c release
from the mitochondria, which is requested in most apoptotic
pathways to activate caspase-3 through caspase-9 activation, are
associated with multidrug resistance. Accordingly, expression of
caspase-3 in the human MCF-7 breast tumor cell line (which is
deficient for caspase-3) restores the apoptotic response to the
topoisomerase II inhibitor, etoposide [7–9]. Caspase-3 was also
involved in breast cancer cell apoptosis upon exposure to
anthracyclines [9–12] and cisplatin [13–16]. Its role in tumor cell
response to paclitaxel has been challenged [17–24].
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unexplored. We also previously studied the impact of caspase-3s
expression in a population of breast carcinomas treated with
neoadjuvant cyclophosphamide-based chemotherapy and ob-
served an inverse relationship between caspase-3s/caspase-3 ratio
level expression and pathological response [6]. Therefore, the
present study was performed to precise the molecular mechanism
in apoptosis inhibition of caspase-3s by using breast tumor cell
lines MCF-7 treated by various chemotherapeutic agents known to
induce an apoptotic mode of cell death.
Materials and Methods
Cell lines
Human breast cancer cell lines MCF-7 (deficient for caspase-3),
HBL-100 and MDA-MB-231 (proficient for caspase-3) were
purchased from the ATCC (American Type Culture Collection,
Manassas, VA, USA). The cell lines were cultured according to the
manufacturer’s instructions.
Full-length cDNA synthesis and cloning
The full-length of caspase-3 and caspase-3s coding sequences
were obtained using SuperScript
TM One-Step long templates RT-
PCR (Invitrogen, Carlsbad, CA, USA) with 1.25 mg of total RNA
from the UACC3199 cell line (Arizona Cancer Center Tissue
Culture Shared Resource) containing high levels of the two
transcripts. Specific primers used were reported in Table S1. PCR
program was performed by one cycle at 45uC for 30 min, 94uC for
2 min followed by 35 cycles of 15 s at 94uC, 30 s at 50uC, 1 min at
68uC, and one final cycle for 5 min at 72uC (Abi Prism 9700
thermocycler, Applied Biosystems, Foster City, CA, USA). The
two transcripts were separated by a 3% agarose gel electrophoresis
and purified by specific extraction with QIAquick Gel Extraction
Kit (Qiagen, Courtaboeuf, France).
The inserts were cloned into pcDNA3.1/CT-GFP-TOPO or
pcDNA3.1/CT-YFP-TOPO and amplified in One ShotH TOP10
Chemically Competent E. Coli with Fusion TOPOH TA
Expression Kits (Invitrogen). The plasmids from a few randomly
picked colonies were isolated. The orientations of the caspase-3 or
caspase-3s fragments were tested by PCR and automatic
sequencing as described below.
Stable transfection
For stable transfection, 5610
5 MCF-7 and HBL100 cells were
grown in a medium without antibiotics in 12-well plates. Two days
later, cells were transfected with 0.5 mg of plasmid containing
either caspase-3 or caspase-3s insert and with GFP or YFP control
vector. Stable transfections were performed by LipofectAMINE
2000 (Invitrogen) according to manufacturer’s instructions. The
stable colonies were selected by 1000 mg/ml GeneticinH or 10 mg/
ml Blasticidin (Invitrogen). To ensure that the inserts were
sufficiently expressed, the transfection efficiency was controlled
by quantitative real-time RT-PCR amplification, the presence of
GFP and YFP was controlled by microscopy and the presence of
extrinsic caspase-3 and caspase-3s was determined by Western
Blot. Relative change expressions were calculated between control
and transfected cells.
Caspase-3 and caspase-3s extinction by siRNA
HBL100 or MDA-MB-231 cells (3610
4 per wells), which are
proficient for caspase-3, were grown in a medium without
antibiotics in 6-well plates during 2 days. Transfections (procas-
pase-3 siRNA: CGACUUCUUGUAUGCAUACUCCACA, cas-
pase-3s siRNA: GGGTTATTATTCTTGGCGAA) were per-
formed by LipofectAMINE 2000. Twenty four, 48, 72 and
96 hours of extinction were tested by Western Blot (Figure S2A) or
quantitative PCR (Figure S2B). Cytotoxic treatments were
performed during the best extinction time lapse (Figure S2A and
B). For treatment after caspase-3s down-regulation, chemothera-
peutic drug yields were 10 fold inferior to the IC50.
Sequencing of PCR products
The specificity of all PCR amplifications was verified by
sequencing of PCR-products. Briefly, products were excised from
3% agarose gels and isolated as described above. The purified
PCR products were sequenced using the Abi-Prism Big Dye
Terminator Cycle Sequencing Ready Reaction Kit (Applied
Biosystems) with the respective primers used in the initial PCR
according to the manufacturer’s protocol.
RNA extraction, cDNA synthesis, and Quantitative
real-time PCR amplification
Total RNA was extracted with Trizol reagent (Invitrogen) and
its quality was checked by 28S/18S ratio on agarose gel. One
microgram of total RNA was reverse transcribed as previously
described [6].
For real-time PCR, amplification was performed in a total
volume of 25 mL in the presence of 600 nM of each primers,
200 nM of probe, 12.5 mL of Universal Master Mix (Applied
Biosystems), and 12 ng of cDNA (or water as negative control).
PCR was performed with an initial denaturation step of 10 min at
95uC, followed by 40 cycles of 15 s at 95uC and 1 min at 60uC. All
samples were amplified in duplicate and results were analyzed at
the CT level. Control 18S reactions (Applied Biosystems) were
used to normalize DCT values.
Total protein extractions
Total protein extraction was performed by addition of lysis
buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM Sodium pyrophosphate,
1m Mb-Glycerophosphate, 1 mM Na3VO4,1mg/ml Leupeptin,
1 mM PMSF added immediately prior to use) on cell monolayer
for 5 min on ice. Afterwards, the lysate was harvested and
sonicated.
Western Blot analysis
30 mg of protein extracts were separated SDS-PAGE 10%
acrylamide and transferred to PVDF or nitrocellulose membranes
(according to the molecular weight of the protein) with an
electrophoretic transfer apparatus. After blocking with buffer
containing 3% of ECL Advance
TM blocking agent (GE Health-
care, Buckinghamshire UK) in PBS/Tween 0.3% for 1.5 hour at
room temperature, the membrane was probed with specific
polyclonal antibodies (Abcam, Cambridge, UK) diluted in
blocking solution (b-actin 1/25000, caspase-3 1/7500, GFP 1/
50000, caspase-9 1/1000, APAF-1 1/1000, lamin A 1/4000, or a-
fodrin 1/2000) for 1 hour at room temperature. The antibody
used for procaspase-3 and caspase-3 detection was generated with
the epitope residues between amino acids 161 and 175. This part
of the protein is common to procaspase-3 and caspase-3 as it is
located in the large subunit.
The GFP antibody recognizes YFP in YFP transfected cells and
thus the caspase-3s YFP tag. Next, the membrane was incubated
with biotinylated anti-rabbit IgG (1:50000 in blocking solution)
secondary antibody (Invitrogen) 30 min at room temperature.
Then, the membrane was probed with streptavidin-HRP (1/
50000) for 15 min at room temperature in PBS/Tween 0.3%.
Caspase-3s Inhibits Apoptosome Assembly
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(ECL Advance
TM Western Blotting Detection Kit; GE Health-
care) and Chemidoc XSR device (Bio-Rad).
Flow cytometric assessment of apoptosis after dual
staining with Annexin-V-PE and 7AAD
Apoptosis was induced by a large scale of chemotherapeutic
drugs in the two cell lines (MCF-7 and HBL100) (Table S2).
Assessment of apoptosis was accomplished by measuring Annexin-
V-PE and 7AAD staining (Apoptosis Detection Kit I BD
Pharmingen
TM, Franklin Lakes (NJ), USA) according to manu-
facturer’s instructions. Cells (30 000) were counted by flow
cytometry using Becton Dickinson LSRII and the experiments
were performed in triplicate in two different clones.
Immunoprecipitation assays (IP)
IP assays were carried out on total protein extract of HBL100
cell line with Exacta Cruz matrix (Tebu-bio, Le Perray En
Yvelines, France) according to manufacturer’s instructions and
analyzed by western blot.
Fluorescence microscopy
Wild-type, non tagged procaspase-3 or caspase-3s stably
transfected MCF-7 cells were transiently transfected with procas-
pase-3-GFP or caspase-3s-YFP. Cells were plated onto 6-well
plates for 24 hours, then treated or not with anticancer drugs for
indicated times before replacing the culture medium with phenol
red-free medium. Cells were scanned in phase contrast, and with a
GFP or YFP filter under UV light.
Statistical analysis
Data were analyzed using the student t test on the Statview 5.0
software.
Results
Caspase-3s inhibits drug-induced apoptosis in breast
cancer cells
We previously showed that in breast carcinoma, increase in
caspase-3s/caspase3 ratio expression was significantly associated
with chemoresistance to cyclophosphamide-based neoadjuvant
treatment [6]. To go further, procaspase-3 and caspase-3s were
stably transfected, either alone or in combination in MCF-7 cells.
The constructs were fused to GFP (pro-caspase-3) or YFP (caspase-
3s) and the GFP vector was used as a control (Figure S1).
Transfected MCF-7 cells were exposed to the topoisomerase II
inhibitor etoposide, the tubulin poison vinblastine and the folate
metabolism inhibitor methotrexate for 48 hours before analyzing
apoptosis induction by the use of a flow cytometry assay.
Expression of procaspase-3 cDNA strongly increased the ability
of MCF-7 to undergo apoptosis in response to etoposide and
methotrexate but did not demonstrate any significant effect on
vinblastine-induced cell death in the tested conditions or slightly
enhanced their apoptotic response to some of the drugs used
(Figure 1A, light grey bars). Expression of the caspase-3s either did
not sensitize the cells to drug-induced apoptosis (Figure 1A, black
bars). Remarkably, co-expression of both procaspase-3 and
caspase-3s completely suppressed the ability of procaspase-3
expression to sensitize MCF-7 cells to etoposide and methotrex-
ate-induced cell death (Figure 1A, dark grey bars). These results
were further completed by studying the consequences of caspase-
3s and/or procaspase-3 expression on apoptosis induced by a
series of other cytotoxic agents in MCF-7 and HBL100 cells. Both
cell lines demonstrated specific profiles of sensitivity to drug-
induced apoptosis. While procaspase-3 expression (in MCF-7) or
overexpression (in HBL100) increased their apoptotic response to
cytotoxic agents (5FU, Bleomycin, Cisplatine, Epirubicin, Vin-
cristine or Staurosporine), expression of caspase-3s always
counteracted this sensitization (Table S3). Moreover, siRNA
experiments targeting a sequence located in the caspase-3 specific
exon 6 or a specific sequence of caspase-3s, to down-regulate the
expression of procaspase-3 or caspase-3s respectively, in HBL100
cells were performed to determine the effect of endogenous
Figure 1. Caspase-3s inhibits drug-induced apoptosis. A. MCF-7
cells were stably transfected with GFP vector (white), procaspase-3-GFP
(light grey), caspase-3s-YFP (black) or with C3-GFP and C3s-YFP (dark
grey) and treated with etoposide, vinblastine or methotrexate for 48 H.
B. HBL100 WT cells (white) were transfected either with scRNA (grey) or
with siRNA against procaspase-3 (black). The efficiency of procaspase-3
extinction is shown in the small inset. Apoptosis was next induced by
etoposide, vinblastine or methotrexate and detected by flow cytometry.
Asterisks correspond to p,0.01. C. HBL100 and MDA-MB-231 cells
(white) were transfected either with scRNA (white) or with siRNA
against caspase-3s (black). The efficiency of caspase-3s extinction is
shown in the small inset. Apoptosis was next induced by etoposide,
vinblastine or methotrexate and detected by flow cytometry. The drug
used yields in panel C were 10 fold inferior than the IC50 used in panel
B, explaining the differences between controls of panels B and C.
Asterisks correspond to p,0.01.
doi:10.1371/journal.pone.0029058.g001
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etoposide, vinblastine and methotrexate for 48 hours. In absence
of procaspase-3 (Figure 1B), HBL100 cells were less sensitive to
apoptosis induced by etoposide and methotrexate. As expected, in
absence of caspase-3s (Figure 1C), both HBL100 and MDA-MB-
231 cells were more sensitive to etoposide and methotrexate
induced apoptosis, confirming that endogenous caspase-3s plays
an important role in caspase-3 dependant apoptosis regulation.
Caspase-3s prevents procaspase-3 activation
We first analyzed procaspase-3 activation in treated MCF-7
cells transfected with pro-caspase-3-GFP or with caspase-3s-YFP.
Whereas vinblastine did not demonstrate any effect on procaspase-
3 activation (Figure 2A, fifth and sixth tracks), exposure to
etoposide and methotrexate induced the proteolytic cleavage of
the procaspase-3-GFP into a p40 fragment indicating the
activation of caspase-3-GFP (Figure 2A, third and seventh tracks).
The expression of caspase-3s-YFP with caspase-3-GFP prevented
the ability of etoposide and methotrexate to trigger the proteolytic
cleavage of the proenzyme (Figure 2A, fourth and eighth tracks).
In procaspase-3 proficient cells, etoposide and methotrexate
induced the cleavage of caspase-3 specific substrates, the
70 KDa Lamin-A into a 28 KDa fragment and the cleavage of
the 250 kDa a-Fodrin into a 160 kDa fragment [25,26]. These
cleavages were not observed in MCF-7 cells expressing only
caspase-3s and in those expressing both procaspase-3 and caspase-
3s in response to etoposide (Figure 2B) and methotrexate
(Figure 2D). Vinblastine treatment had not effect on Lamin-A
and a-Fodrin cleavage (Figure 2C) whatever the pro-caspase-3 or
caspase-3s expression.
Caspase-3s influences procaspase-3 location
Fluorescent microscopyanalyses ofMCF-7 cells indicatedthat,in
theabsenceofanytreatment,procaspase-3-GFP was located mainly
in the cytoplasm (Figure 3A, first line), whereas caspase-3s-YFP was
in both nucleus and cytoplasm (Figure 3B, first line). Upon exposure
to etoposide or methotrexate for 10 hours, part of the GFP-tagged
caspase-3 was translocated into the nucleus (Figure 3A, second and
fourth lines). After vinblastine exposure, GFP-tagged procaspase-3
remained in the cytoplasm (Figure 3A, third line). Caspase-3s
Figure 2. Caspase-3s prevents procaspase-3 activation. A. MCF-7 cells stably transfected with caspase-3 were treated with etoposide,
vinblastine or methotrexate (lanes 1, 3, 5 and 7). Caspase-3 was cleaved in procaspase-3 transfected cells after 48 hour treatment with etoposide, or
methotrexate but not after vinblastine treatment. In procaspase-3-GFP/C3s-YFP co-transfected treated MCF-7 cells (lanes 2, 4, 6, and 8), procaspase-3
cleavage was completely abolished. b-actin was used as loading control. B–D. Analysis of lamin-A and a-fodrin cleavage by Western Blot. GFP MCF-7
cells, procaspase-3-GFP (ProC3-GFP) or caspase-3s-YFP (C3s-YFP) transfected cells were treated with etoposide (B), vinblastine (C) or Methotrexate (D)
during 48 hours. Lamin-A and a-fodrin were cleaved only in single procaspase-3-GFP transfected cells treated with etoposide or Methotrexate. ProC3-
GFP/C3s-YFP co-transfected cells treated with etoposide or methotrexate did not show cleavage of neither lamin-A nor a-fodrin. In accordance with
panel A, vinblastine did not induce cleavage of neither lamin-A nor a-fodrin b-actin was used as loading control.
doi:10.1371/journal.pone.0029058.g002
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third and fourth lines). When non tagged caspase-3s was stably
expressed in MCF-7 cells before transient expression of GFP-tagged
procaspase-3, the fluorescent procaspase-3 was located in both
nucleus and cytoplasm and exposure to the tested drugs did not
change this subcellular repartition (Figure 3C). As expected, when
nontaggedprocaspase-3 was stably expressed inMCF-7cells before
transient expression of YFP-tagged caspase-3s, the fluorescent
caspase-3s was located in both nucleus and cytoplasm and again,
exposure to the tested drugs did not change significantly this
subcellular repartition (Figure 3D). The fluorescent nuclear staining
quantification is shown in Table S4.
Caspase-3s structure predicts an absence of catalytic
activity
To understand why caspase-3s has no catalytic activity, we
studied its protein sequence and structure. As shown in Figure 4A,
caspase-3s has no catalytic site compared with procaspase-3, and
especially the cysteine residue that is crucial for the catalytic
activity of caspases. Moreover, caspase-3s does not possess the
cleavage site between the small and the large subunit, resulting in
an absence of cleavage into two subunits. Finally, in the caspase-
3s, there are no sites for binding of caspase inhibitors such as Ac-
DEVD-CHO [27], XIAP [28]… However, caspase-3s possesses
the same pro-domain as procaspase-3, but, contrary to procas-
pase-3, caspase-3s pro-domain is not cleaved. Indeed, the
activation of procaspase-3 is sequential. The first step is the
cleavage between the large and the small subunits. Once this
cleavage is done, the large+small subunit complex induces the
cleavage of the pro-domain, involving the activation of caspase-3.
Thus, if the protein is not divided in two subunits, the pro-
domain can not be cleaved. Therefore, the absence of caspase-3s
pro-domain cleavage may be explained by the absence of
caspase-3s cleavage in two subunits.
Figure 3. Caspase-3s influences the localization of procaspase-3. Twenty-four hours after GFP-coupled procaspase-3 (C3-GFP) or YFP-
coupled caspase-3s (C3s-YFP) transfection in parental MCF-7 cells (A and B respectively) or in non tagged caspase-3s (C3s) or procaspase-3 (C3) stably
transfected MCF-7 cells (C and D respectively) MCF-7 cells were treated or not with etoposide, vinblastine or methotrexate for 10 hours. Cells were
scanned in phase contrast and with a GFP or YFP filter under UV light. Nuclei were delimited by dotted lines. The nulear staining quantification is
presented in Table S4.
doi:10.1371/journal.pone.0029058.g003
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has a strong impact on the 3D structure. In fact, when the pro-
caspase-3 3D structure was compared with the caspase-3s one, it
appeared that caspase-3s lacked 2 b-sheets and 2 a-helixes
compared with procaspase-3 (Figure 4B). These structures are
necessary for the catalytic activity of caspase-3.
Caspase-3s interacts with procaspase-3 and prevents its
interaction with apoptosome
To understand the apoptosis inhibition mechanism of caspase-3s,
co-immunoprecipitation experiments were performed in HBL100
cells stably transfected with YFP-coupled caspase-3s. Using an anti-
caspase-3 monoclonal antibody that targets an epitope located in
the short subunit of caspase-3, detecting only procaspase-3 and
active caspase-3 but not caspase-3s, we observed, upon exposure to
etoposide and methotrexate, caspase-3s interacted with procaspase-
3 (Figure 5A). Moreover, co-immunoprecipitation experiments with
an anti-GFP antibody (that recognizes caspase-3s tag) demonstrated
that, in cells exposed to etoposide or methotrexate, caspase-3s-YFP
could pull down procaspase-3 (Figure 5B).
Then, we wondered whether the interaction of caspase-3s with
procaspase-3 prevents pro-caspase-3 activation by inhibiting
Figure 4. Protein sequence and 3D structure of procaspase-3 and caspase-3s. A. Alignment of procaspase-3 (C3) and caspase-3s (C3s)
amino acid sequences. Prodomain is framed, amino acids forming the catalytic site are in bold blue, interaction sites with caspase-3 inhibitors are in
bold green [27–28], cleavage site between small and large subunits are in bold and underlined [28], aspartate residue cleaved during activation are in
bold red [29]. B. 3D structure of procaspase-3 and caspase-3s. Bold arrows represent the end of common sequence between both proteins and pink
asterisks show the b-sheets and a-helixes present in procaspase-3 and absent in caspase-3s.
doi:10.1371/journal.pone.0029058.g004
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HBL100 cells stably transfected with caspase-3s-YFP or YFP alone and treated with etoposide, vinblastine or methotrexate for 48 hours. A. In YFP
transfected cells, immunoprecipitations were performed with anti-caspase-3 antibody and western blot with anti-GFP (that recognizes YFP in YFP
transfected cells and the caspase-3s YFP tag) and anti-caspase-3 antibodies. The results revealed no interaction between caspase-3 and YFP with or
without treatment. In HBL100 transfected with caspase-3s-YFP, an interaction between procaspase-3 and caspase-3s after etoposide or methotrexate
treatments was observed. B. In YFP transfected cells, immunoprecipitations were performed with anti-GFP antibody and western blot with anti-
caspase-3 and anti-GFP antibodies. The results revealed no interaction between YFP and procaspase-3 whatever the conditions. In caspase-3s-YFP
transfected HBL100, an interaction between caspase-3s and procaspase-3 was observed after etoposide or methotrexate treatment. C–F. MCF-7 cells
were transfected with empty-vector (YFP), procaspase-3 (ProC3) or caspase-3s-YFP (C3s-YFP) or both caspase-3s-YFP and procaspase-3. The cells were
treated or not with etoposide. C. Immunoprecipitations were performed with anti-active caspase-9 antibody and western blot with anti-active
caspase-9, anti-Apaf-1, anti-caspase3 and anti-GFP (that recognizes caspase-3s tag) antibodies. The results showed that procaspase-3 and caspase-3s
interacted, in treated cells, with active caspase-9 and anti-Apaf-1 only when they are alone. As soon as caspase-3s and procaspase-3 are present at the
same time, the interaction with active caspase-9 and anti-Apaf-1 was abolished. D. Immunoprecipitations were performed with anti-caspase-3
antibody and western blot with anti-caspase-3, anti-Apaf-1, and anti-active caspase-9 antibodies. The results showed that procaspase-3 interacted
with active caspase-9 and anti-Apaf-1 in treated cells only in absence of caspase-3s. E. Immunoprecipitations were performed with anti-GFP antibody
and western blot with anti-GFP, anti-Apaf-1 and anti-active caspase-9 antibodies. The results showed that YFP did not interact with active caspase-9
and anti-Apaf-1 whereas caspase-3s interacted with active caspase-9 and anti-Apaf-1 in treated cells only in absence of procaspase-3. F.
Immunoprecipitations were performed with anti-Apaf-1 antibody and western blot with anti-Apaf-1, anti-active caspase-9, anti-caspase-3 and anti-
GFP antibodies. The results showed that procaspase-3 and caspase-3s interacted, in treated cells, with active Apaf-1 and caspase-9 only when they
are alone. As soon as caspase-3s and procaspase-3 are present at the same time, the interaction with Apaf-1 and active caspase-9 was abrogated.
doi:10.1371/journal.pone.0029058.g005
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with a vector encoding either YFP alone or the YFP-tagged
caspase-3s or procaspase-3 without any tag. These cells were left
untreated or treated with etoposide for 48 hours. Afterwards, cell
lysates were immunoprecipitated with an anti-active caspase-9
antibody and Apaf-1 antibody representing the Apaf-1/cyto-
chrome c/caspase-9 complex, precursor of apoptosome. The
active form of caspase-9 was detected by immunoblot analysis in
etoposide treated cells (Figure 5C, Active caspase-9 panel) and its
interaction with Apaf-1 was confirmed in etoposide treated
samples (Figure 5C, APAF-1 panel). The results showed an
interaction between active caspase-9/Apaf-1 and procaspase-3 (as
detected with an anti-procaspase-3 antibody) or caspase-3s (as
detected with an anti-GFP antibody, recognizing caspase-3s tag)
when these proteins were expressed alone in etoposide-treated
cells. These interactions were no more detected when both
procaspase-3 and caspase-3s were expressed simultaneously
(Figure 5C, Procaspase-3 and C3s-YFP panels). The results were
confirmed by inverse immunoprecipitation with an anti-procas-
pase-3 antibody (Figure 5D), an anti-GFP antibody (Figure 5E),
Figure 6. Model of apoptosis inhibition by caspase-3s. After apoptotic signal, cytochrome c is released from mitochondria to the cytoplasm.
Then, Apaf-1/cytochrome c oligomers are formed and interact with caspase-9. In presence of procaspase-3 only, the complex Apaf-1/cytochrome c/
active caspase-9 interacts with procaspase-3 to form the complete apoptosome. Then, active caspase-3 is release from the complex and apoptosis
occurs. In presence of caspase-3s, the complex Apaf-1/cytochrome c/active caspase-9 interacts with caspase-3s to form a ‘‘short’’ apoptosome having
not the ability to induce apoptosis. Finally, in presence of both procaspase-3 and caspase-3s, caspase3s interacts with procaspase-3. This interaction
induces the sequestration of procaspase-3, inhibiting the complete apoptosome assembly.
doi:10.1371/journal.pone.0029058.g006
Caspase-3s Inhibits Apoptosome Assembly
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e29058and an anti-Apaf-1 antibody (Figure 5F). These results suggested
that caspase-3s prevent the apoptosome assembly by sequestrat-
ing procaspase-3.
Discussion
A variety of mechanisms has been described to account for the
resistance of breast cancer cells as well as other tumor types to
anticancer agents. Indeed, patients often develop drug resistance
towards drugs of unrelated structures and activities. To fight
against chemotherapy, cancer cells are able to develop various
mechanisms of resistance such as activation of survival pathways
or apoptosis resistance. Apoptosis resistance can reflect resistance
to chemotherapeutic treatments [1]. Caspase-3 is a major pro-
apoptotic protein and is a key enzyme in drug-induced apoptosis
of tumor cells [9]. In contrast, caspase-3s overexpression in breast
carcinomas might be indicative of chemoresistance to neoadjuvant
cyclophosphamide-containing treatment [6]. Thus, it was suggest-
ed that caspase-3s might be an apoptosis protagonist which could
be a new predictive marker of apoptosis resistance. To evaluate
this hypothesis, the ability of caspase-3s to counteract apoptosis
induced by various pro-apoptotic chemotherapeutic drugs was
evaluated in this study with the use of breast tumor cell lines which
are deficient or proficient for caspase-3.
The present study demonstrates that caspase-3s, generated by
alternative splicing of caspase-3 pre-mRNA, negatively interferes
with caspase-3 activation and apoptosis in breast cancer cells
exposed to cytotoxic drugs. This effect appears to involve an
interaction of caspase-3s with procaspase-3 that prevents its
recruitment in the apoptosome and its activation.
Our results confirm and extend the observation that procaspase-
3 expression in MCF-7 cells, which do not express spontaneously
this protease, enhances the cell ability to undergo cell death in
response to etoposide, methotrexate and other cytotoxic drugs
[30]. Caspase-3 activation was confirmed by immunoblot showing
the proteolytic cleavage of the protein. The cleavage of a-fodrin
and lamin A, which was described as caspase-3 targets, also argues
for a role of caspase-3 in these apoptotic pathways. In addition,
siRNA-mediated down-regulation of caspase-3 in HBL100
decreased the apoptotic response to the drugs used, whereas
caspase-3s expression inhibition increases cell death induced by
the treatment in HBL100 and MDA-MB-231. It is important to
note that there are no differences between HBL100 and MDA-
MB-231 cells in expression of other apoptotic factor analyzed in
this study. In MCF-7 cells, caspase-3 is absent and caspases-4 and -
10 are downregulated. Nevertheless, as caspase-4 is an inflamma-
tory caspase and caspase-10 is only involved in extrinsic apoptosis
pathway, both these proteins have no influence on the studied
apoptosis pathway.
In apoptosis involving the mitochondrial pathway, procaspase-3
is activated by caspase-9, subsequently to apoptosome formation
[31]. Thus, it was of interest to precise the interaction between
caspase-3s, pro-caspase-3 and/or caspase-9. Indeed, the ability of
caspase-3s to interact with pro-caspase-3 and/or caspase-9 might,
at least in part, contribute to explain its anti-apoptotic activity. We
observed that procaspase-3 or caspase-3s expressed in MCF-7 cells
interacted with active caspase-9 when these cells were exposed to
apoptotic stimuli. This interaction was abrogated when caspase-3s
and procaspase-3 are expressed simultaneously. These observa-
tions could suggest that interaction of active caspase-9 with a
catalytically inactive caspase-3s could stimulate caspase-9 activity
or activation at the apoptosome level explaining why, in MCF-7,
the overexpression of caspase-3s alone increased slightly apoptosis
rate. However this situation was observed only in MCF-7, which is
deficient for caspase-3, and not in HBL100 as caspase-3s is
expressed with procaspase-3 (Table S3). Nevertheless, in human
tissues, caspase-3s is always expressed with procaspase-3. Taken
together, these results strongly suggested that caspase-3s prevent
the apoptosome assembly by sequestrating procaspase-3. These
data evocate the mechanism of caspase-9 gene which also
possesses a splice variant with antagonist apoptotic properties to
the principal transcript. Indeed,, casp9-c, an alternative splice
variant of caspase-9, functions as an endogenous apoptotic
inhibitor by interfering with the Apaf-1/procaspase-9 interaction
[32]. Similarly, forced expression of the caspase-8 alternative splice
variant, caspase-8L, protected hematopoietic cells from extrinsic
apoptosis by preventing CD95 to connect to the caspase cascade
[33].
In conclusion, our study indicates that caspase-3s could have its
anti-apoptotic function by sequestration of procaspase-3, inhibit-
ing the interaction of procasase-3 with caspase-9 and apoptosome,
thus counteracting the activation of the apoptotic machinery
(Figure 6). Our data support that the investigation of caspase-3s in
breast tumors might contribute to explain certain forms of drug
resistance, and to develop more adapted and efficient treatments.
Supporting Information
Figure S1 Control of transfection by Western Blot assay
with anti-GFP antibody in MCF-7 cell line. Procaspase-3-
GFP (ProC3-GFP) and caspase-3s-YFP (C3s-YFP) were stably
overexpressed in single transfection and in co-transfection. GFP
vector (GFP) was used as control. b-actin was used as loading
control.
(TIF)
Figure S2 Control of procaspase-3 and capsase-3s
extinction after siRNA transfection. A. Endogenous procas-
pase-3 was inactivated in HBL100 cells by siRNA transfection and
the expression was monitored every 24 hours by western blot
analysis from 24 to 96 hours after transfection. The transfection of
siRNA induced the complete extinction of procaspase-3 from 48 to
96 hours after transfection. Caspase-3s expression was not affected
by procaspase-3 siRNA transfection. B. Endogenous caspase-3s
was inactivated in HBL100 and MDA-MB-231 cells by siRNA
transfection and the expression was monitored every 24 hours up
to 96 hours by real time quantitative PCR. The transfection of
siRNA induced the complete extinction of caspase-3s from 48 to
96 hours after transfection. Nonetheless, procaspase-3 expression
was not down-regulated by caspase-3s siRNA transfection, but its
expression was strongly increased. C. The extinction of endoge-
nous caspase-3s induced a strong increase of the endogenous
procaspase-3/caspase-3s ratio. Double arrows indicate the optimal
time lapse for cytotoxicity assay.
(TIF)
Table S1 Primers and probes sequences used in this study.
(DOC)
Table S2 Chemotherapeutic agents and doses used in this study
to induce apoptosis.
(DOC)
Table S3 The cells (MCF7: deficient for caspase-3; HBL100:
proficient for caspase-3) were incubated for 48 H in drug-
containing medium and apoptosis was detected by flow cytometry.
*Data represent the percentage (6 Standard Deviation) of
apoptotic cells in each treatment conditions (mean of 3
experiments). CT: control, 5FU: 5- Fluorouracil, BLM: Bleomy-
cine, CDDP: Cisplatin, EPI: Epirubicin, DOC: Docetaxol, VIN:
Vincristine, STAU: Staurosporine. For the different drugs, the
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and HBL100, and are thus indicated in Table S2.
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Table S4 Numbers indicate the mean fluorescence intensity of
nuclei for each condition.
(DOC)
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